Wave Life Sciences Ltd.

DB:1U5 Stock Report

Market Cap: €1.2b

Wave Life Sciences Valuation

Is 1U5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1U5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 1U5's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 1U5's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1U5?

Key metric: As 1U5 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1U5. This is calculated by dividing 1U5's market cap by their current revenue.
What is 1U5's PS Ratio?
PS Ratio18.9x
SalesUS$71.80m
Market CapUS$1.45b

Price to Sales Ratio vs Peers

How does 1U5's PS Ratio compare to its peers?

The above table shows the PS ratio for 1U5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.3x
DMP Dermapharm Holding
1.9x3.63%€2.3b
28L PEPTONIC medical
1.4xn/a€560.2m
HIGH Cantourage Group
37.3x22.27%€72.8m
BAYN Bayer
0.8x2.25%€35.7b
1U5 Wave Life Sciences
18.9x46.23%€1.4b

Price-To-Sales vs Peers: 1U5 is expensive based on its Price-To-Sales Ratio (18.9x) compared to the peer average (10.3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 1U5's PS Ratio compare vs other companies in the DE Pharmaceuticals Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
NV5 AcuCort
0.3xn/aUS$239.71m
VP2 Valeo Pharma
0.01x20.92%US$520.38k
L7R Lipidor
0.2xn/aUS$92.68k
7IZ Ziccum
0.06xn/aUS$30.58k
No more companies available in this PS range
1U5 18.9xIndustry Avg. 4.0xNo. of Companies4PS01.22.43.64.86+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1U5 is expensive based on its Price-To-Sales Ratio (18.9x) compared to the European Pharmaceuticals industry average (4x).

Price to Sales Ratio vs Fair Ratio

What is 1U5's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1U5 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.9x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: 1U5 is expensive based on its Price-To-Sales Ratio (18.9x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1U5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.10
€19.81
+224.70%
45.58%€44.54€10.28n/a16
Apr ’27€6.20
€22.91
+269.50%
45.64%€44.90€9.50n/a15
Mar ’27€13.50
€28.23
+109.13%
21.00%€42.30€18.61n/a16
Feb ’27€10.50
€27.27
+159.72%
20.28%€42.09€18.52n/a15
Jan ’27€14.80
€26.99
+82.36%
22.22%€42.71€17.94n/a15
Dec ’26€6.35
€17.06
+168.72%
32.53%€31.02€7.76n/a15
Nov ’26€6.85
€17.12
+149.91%
32.32%€31.13€7.78n/a15
Oct ’26€6.25
€16.92
+170.71%
32.32%€30.76€7.69n/a15
Sep ’26€8.15
€17.31
+112.40%
30.77%€30.95€7.74n/a15
Aug ’26€6.60
€17.75
+168.93%
30.55%€31.53€7.88n/a15
Jul ’26€5.20
€17.29
+232.50%
33.13%€30.54€7.63n/a13
Jun ’26€5.25
€18.60
+254.21%
30.94%€31.76€7.94n/a13
May ’26€6.20
€18.59
+199.84%
30.18%€31.64€8.79n/a13
Apr ’26€7.00
€21.56
+207.93%
21.84%€33.34€12.97€6.2011
Mar ’26€9.85
€21.78
+121.16%
21.42%€34.23€14.26€13.5011
Feb ’26€11.40
€21.36
+87.34%
22.32%€34.02€14.18€10.5010
Jan ’26€12.20
€21.36
+75.06%
22.32%€34.02€14.18€14.8010
Dec ’25€14.10
€21.12
+49.77%
23.13%€34.09€14.21€6.3510
Nov ’25€12.60
€18.08
+43.52%
13.01%€20.34€13.87€6.859
Oct ’25€7.30
€13.17
+80.35%
32.91%€19.70€4.48€6.2510
Sep ’25€5.10
€12.14
+137.95%
31.29%€17.40€4.58€8.158
Aug ’25€6.05
€12.53
+107.11%
32.79%€17.73€4.67€6.607
Jul ’25€4.78
€12.53
+162.14%
32.79%€17.73€4.67€5.207
Jun ’25€5.65
€11.82
+109.13%
33.37%€17.46€4.60€5.257
May ’25€4.50
€11.90
+164.45%
35.81%€17.39€4.58€6.206
Apr ’25€5.55
€11.90
+114.42%
35.81%€17.39€4.58€7.006
€20.02
Fair Value
69.5% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/29 14:32
End of Day Share Price 2026/04/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Wave Life Sciences Ltd. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Madison Wynne El-SaadiB. Riley Securities, Inc.
Whitney IjemCanaccord Genuity